Core Viewpoint - 旺山旺水-B plans to globally offer 17.5978 million H-shares, with a price range of HKD 32.00 to 34.00 per share, aiming for a listing on November 6, 2025 [1] Company Overview - 旺山旺水-B, established in 2013, is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs in the fields of neuropsychiatry and reproductive health [1] - The company has two core products: LV232, a 5-HTT/5-HT3 receptor modulator for treating major depressive disorder, and TPN171, a PDE5 inhibitor for treating erectile dysfunction [1] Product Pipeline - In addition to the core products, the company has four candidate drugs in clinical stages and three in preclinical stages [1] Fundraising and Use of Proceeds - The expected net proceeds from the offering are approximately HKD 521.1 million, which will be allocated as follows: 38.0% for core product R&D, 27.0% for other candidate product R&D, 10.0% for the construction of the Qingdao factory, 15.0% for enhancing sales and marketing capabilities, and 10.0% for working capital [1]
旺山旺水-B启动招股 拟全球发售1759.78万股H股
Zheng Quan Shi Bao Wang·2025-10-28 00:56